31 results on '"Savastano, S"'
Search Results
2. Continuous stellate ganglion block for ventricular arrhythmias: case series, systematic review, and differences from thoracic epidural anaesthesia.
- Author
-
Dusi V, Angelini F, Baldi E, Toscano A, Gravinese C, Frea S, Compagnoni S, Morena A, Saglietto A, Balzani E, Giunta M, Costamagna A, Rinaldi M, Trompeo AC, Rordorf R, Anselmino M, Savastano S, and De Ferrari GM
- Abstract
Aims: Percutaneous stellate ganglion block (PSGB) through single-bolus injection and thoracic epidural anaesthesia (TEA) have been proposed for the acute management of refractory ventricular arrhythmias (VAs). However, data on continuous PSGB (C-PSGB) are scant. The aim of this study is to report our dual-centre experience with C-PSGB and to perform a systematic review on C-PSGB and TEA., Methods and Results: Consecutive patients receiving C-PSGB at two centres were enrolled. The systematic literature review follows the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. Our case series (26 patients, 88% male, 60 ± 16 years, all with advanced structural heart disease, left ventricular ejection fraction 23 ± 11%, 32 C-PSGBs performed, with a median duration of 3 days) shows that C-PSGB is feasible and safe and leads to complete VAs suppression in 59% and to overall clinical benefit in 94% of cases. Overall, 61 patients received 68 C-PSGBs and 22 TEA, with complete VA suppression in 63% of C-PSGBs (61% of patients). Most TEA procedures (55%) were performed on intubated patients, as opposed to 28% of C-PSGBs (P = 0.02); 63% of cases were on full anticoagulation at C-PSGB, none at TEA (P < 0.001). Ropivacaine and lidocaine were the most used drugs for C-PSGB, and the available data support a starting dose of 12 and 100 mg/h, respectively. No major complications occurred, yet TEA discontinuation rate due to side effects was higher than C-PSGB (18 vs. 1%, P = 0.01)., Conclusion: Continuous PSGB seems feasible, safe, and effective for the acute management of refractory VAs. The antiarrhythmic effect may be accomplished with less concerns for concomitant anticoagulation compared with TEA and with a lower side-effect related discontinuation rate., Competing Interests: Conflict of interest: none declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
3. Electrical storm treatment by percutaneous stellate ganglion block: the STAR study.
- Author
-
Savastano S, Baldi E, Compagnoni S, Rordorf R, Sanzo A, Gentile FR, Dusi V, Frea S, Gravinese C, Cauti FM, Iannopollo G, De Sensi F, Gandolfi E, Frigerio L, Crea P, Zagari D, Casula M, Sangiorgi G, Persampieri S, Dell'Era G, Patti G, Colombo C, Mugnai G, Notaristefano F, Barengo A, Falcetti R, Perego GB, D'Angelo G, Tanese N, Currao A, Sgromo V, and De Ferrari GM
- Subjects
- Aged, Female, Humans, Male, Prospective Studies, Stellate Ganglion, Stroke Volume, Treatment Outcome, Ventricular Fibrillation etiology, Ventricular Function, Left, Middle Aged, Tachycardia, Ventricular therapy, Tachycardia, Ventricular etiology
- Abstract
Background and Aims: An electrical storm (ES) is a clinical emergency with a paucity of established treatment options. Despite initial encouraging reports about the safety and effectiveness of percutaneous stellate ganglion block (PSGB), many questions remained unsettled and evidence from a prospective multicentre study was still lacking. For these purposes, the STAR study was designed., Methods: This is a multicentre observational study enrolling patients suffering from an ES refractory to standard treatment from 1 July 2017 to 30 June 2023. The primary outcome was the reduction of treated arrhythmic events by at least 50% comparing the 12 h following PSGB with the 12 h before the procedure. STAR operators were specifically trained to both the anterior anatomical and the lateral ultrasound-guided approach., Results: A total of 131 patients from 19 centres were enrolled and underwent 184 PSGBs. Patients were mainly male (83.2%) with a median age of 68 (63.8-69.2) years and a depressed left ventricular ejection fraction (25.0 ± 12.3%). The primary outcome was reached in 92% of patients, and the median reduction of arrhythmic episodes between 12 h before and after PSGB was 100% (interquartile range -100% to -92.3%). Arrhythmic episodes requiring treatment were significantly reduced comparing 12 h before the first PSGB with 12 h after the last procedure [six (3-15.8) vs. 0 (0-1), P < .0001] and comparing 1 h before with 1 h after each procedure [2 (0-6) vs. 0 (0-0), P < .001]. One major complication occurred (0.5%)., Conclusions: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Long-term outcome of catheter ablation for atrial fibrillation in patients with severe left atrial enlargement and reduced left ventricular ejection fraction.
- Author
-
Demarchi A, Neumann L, Rordorf R, Conte G, Sanzo A, Özkartal T, Savastano S, Regoli F, Vicentini A, Caputo ML, Klersy C, Petracci B, Piciacchia F, Bruno J, Baldi E, D'Amore S, and Auricchio A
- Subjects
- Heart Atria diagnostic imaging, Heart Atria surgery, Humans, Recurrence, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation methods, Pulmonary Veins surgery
- Abstract
Aims: Data regarding the efficacy of catheter ablation in heart failure patients with severely dilated left atrium and reduced left ventricular ejection fraction (LVEF) are scanty. We sought to assess the efficacy of catheter ablation in patients with reduced LVEF and severe left atrial (LA) enlargement, and to compare it to those patients with preserved left ventricular function and equally dilated left atrium., Methods and Results: Three patient groups with paroxysmal or persistent atrial fibrillation (AF) undergoing a first pulmonary vein isolation (PVI) were considered: Group 1 included patients with normal or mildly abnormal LA volume (≤41 mL/m2) and normal LVEF; Group 2 included patients with severe LA enlargement (>48 mL/m2) and normal LVEF; and Group 3 included patients with severe LA enlargement and reduced LVEF. Time to event analysis was used to investigate AF recurrences. The study cohort includes 439 patients; Group 3 had a higher prevalence of cardiovascular risk factors. LA enlargement was associated with a two-fold in risk of AF recurrence, on the contrary only a smaller non-significant increase of 30% was shown with the further addition of LVEF reduction., Conclusions: The long-term outcome of patients with severe LA dilatation and reduced LVEF is comparable to those with severe LA enlargement but preserved LVEF. Long-term efficacy of PVI is certainly affected by the enlargement of the left atrium, but less so by the addition of a reduced LVEF. CA remains the best strategy for rhythm control both in paroxysmal and persistent AF in this subgroup of patients., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
5. Anatomical-based percutaneous left stellate ganglion block in patients with drug-refractory electrical storm and structural heart disease: a single-centre case series.
- Author
-
Savastano S, Dusi V, Baldi E, Rordorf R, Sanzo A, Camporotondo R, Fracchia R, Compagnoni S, Frigerio L, Oltrona Visconti L, and De Ferrari GM
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Stellate Ganglion, Stroke Volume, Ventricular Function, Left, Pharmaceutical Preparations, Tachycardia, Ventricular
- Abstract
Aims: The adoption of percutaneous stellate ganglion blockade for the treatment of drug-refractory electrical storm (ES) has been increasingly reported; however, the time of onset of the anti-arrhythmic effects, the safety of a purely anatomical approach in conscious patients and the additional benefit of repeated procedures remain unclear., Methods and Results: This study included consecutive patients undergoing percutaneous left stellate ganglion blockade (PLSGB) in our centre for drug-refractory ES. Lidocaine, bupivacaine, or a combination of both were injected in the vicinity of the left stellate ganglion. Overall, 18 PLSGBs were performed in 11 patients (age 69 ± 13 years; 63.6% men, left ventricular ejection fraction 31.6 ± 16%). Seven patients received only one PLSGB; three underwent two procedures and one required three PLSGB and two continuous infusions to control ventricular arrhythmias (VAs). All PLSGBs were performed with an anatomical approach; lidocaine, alone, or in combination was used in 77.7% of the procedures. The median burden of VAs 1 h after each block was zero compared with five in the hour before (P < 0.001); 83% of the patients were free from VAs; the efficacy at 24 h increased with repeated blocks. The anti-arrhythmic efficacy of PLSGB was not related to anisocoria. No procedure-related complications were reported., Conclusion: Anatomical-based PLSGB is a safe and rapidly effective treatment for refractory ES; repeated blocks provide additional benefits. Percutaneous left stellate ganglion blockade should be considered for stabilizing patients to allow further ES management., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
6. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests.
- Author
-
Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, Klersy C, Palo A, Contri E, Ronchi V, Beretta G, Reali F, Parogni P, Facchin F, Rizzi U, Bussi D, Ruggeri S, Oltrona Visconti L, and Savastano S
- Subjects
- Aged, Aged, 80 and over, COVID-19, Coronavirus Infections epidemiology, Female, Follow-Up Studies, Humans, Incidence, Italy epidemiology, Male, Out-of-Hospital Cardiac Arrest etiology, Out-of-Hospital Cardiac Arrest therapy, Pneumonia, Viral epidemiology, Prospective Studies, SARS-CoV-2, Betacoronavirus, Cardiopulmonary Resuscitation methods, Coronavirus Infections complications, Emergency Medical Services statistics & numerical data, Out-of-Hospital Cardiac Arrest epidemiology, Pandemics, Pneumonia, Viral complications
- Abstract
Aims: An increase in out-of-hospital cardiac arrest (OHCA) incidence has been reported in the very early phase of the COVID-19 epidemic, but a clear demonstration of a correlation between the increased incidence of OHCA and COVID-19 is missing so far. We aimed to verify whether there is an association between the OHCA difference compared with 2019 and the COVID-19 epidemic curve., Methods and Results: We included all the consecutive OHCAs which occurred in the Provinces of Lodi, Cremona, Pavia, and Mantova in the 2 months following the first documented case of COVID-19 in the Lombardia Region and compared them with those which occurred in the same time frame in 2019. The cumulative incidence of COVID-19 from 21 February to 20 April 2020 in the study territory was 956 COVID-19/100 000 inhabitants and the cumulative incidence of OHCA was 21 cases/100 000 inhabitants, with a 52% increase as compared with 2019 (490 OHCAs in 2020 vs. 321 in 2019). A strong and statistically significant correlation was found between the difference in cumulative incidence of OHCA between 2020 and 2019 per 100 000 inhabitants and the COVID-19 cumulative incidence per 100 000 inhabitants both for the overall territory (ρ 0.87, P < 0.001) and for each province separately (Lodi: ρ 0.98, P < 0.001; Cremona: ρ 0.98, P < 0.001; Pavia: ρ 0.87, P < 0.001; Mantova: ρ 0.81, P < 0.001)., Conclusion: The increase in OHCAs in 2020 is significantly correlated to the COVID-19 pandemic and is coupled with a reduction in short-term outcome. Government and local health authorities should seriously consider our results when planning healthcare strategies to face the epidemic, especially considering the expected recurrent outbreaks., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
7. Percutaneous continuous left stellate ganglion block as an effective bridge to bilateral cardiac sympathetic denervation.
- Author
-
Savastano S, Pugliese L, Baldi E, Dusi V, Tavazzi G, and De Ferrari GM
- Subjects
- Heart, Humans, Sympathectomy, Autonomic Nerve Block, Stellate Ganglion
- Published
- 2020
- Full Text
- View/download PDF
8. Percutaneous stellate ganglion block and extracorporeal cardiopulmonary resuscitation: an effective and safe combination for refractory ventricular fibrillation.
- Author
-
Savastano S, Baldi E, Camporotondo R, Belliato M, Marinoni B, and De Ferrari GM
- Subjects
- Heart, Humans, Stellate Ganglion, Ventricular Fibrillation diagnosis, Ventricular Fibrillation therapy, Cardiopulmonary Resuscitation, Heart Arrest
- Published
- 2020
- Full Text
- View/download PDF
9. AED use before EMS arrival: When survival becomes a matter of law and system in Italy, which can be improved.
- Author
-
Baldi E and Savastano S
- Published
- 2018
- Full Text
- View/download PDF
10. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study.
- Author
-
Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, and Lombardi G
- Subjects
- Acromegaly metabolism, Adult, Cohort Studies, Female, Heart Diseases metabolism, Humans, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular epidemiology, Hypertrophy, Left Ventricular metabolism, Male, Middle Aged, Retrospective Studies, Time Factors, Acromegaly diagnosis, Acromegaly epidemiology, Health Surveys trends, Heart Diseases diagnosis, Heart Diseases epidemiology
- Abstract
Context: The most frequent cause of death in acromegaly is cardiomyopathy., Objective: To evaluate determinants of acromegalic cardiomyopathy., Design: Observational, open, controlled, retrospective study., Subjects: Two hundred and five patients with newly diagnosed active acromegaly (108 women and 97 men; median age 44 years) and 410 non-acromegalic subjects sex- and age-matched with the patients., Main Outcome Measures: Left ventricular (LV) mass index (LVMi), transmitral inflow early-to-atrial (E/A) peak velocity ratio, and LV ejection fraction (LVEF) were measured by Doppler echocardiography to determine the prevalence of LV hypertrophy (LVH), diastolic and systolic dysfunction. The role of age, estimated disease duration, body mass index, GH and IGF1 levels, systolic and diastolic blood pressure, lipid profile and glucose tolerance in determining different features of the acromegalic cardiomyopathy was investigated., Results: Compared with controls, the patients had lower E/A, LVEF, high-density lipoprotein (HDL)-cholesterol levels and higher LVMi, total- and low-density lipoprotein (LDL)-cholesterol, triglycerides, glucose and insulin levels, homeostatic model assessment of insulin resistance (HOMA-R) and HOMA-β. The relative risk to develop mild (odds ratio (OR)=1.67 (1.05-2.66); P=0.027) or severe hypertension (OR=1.58 (1.04-2.32); P=0.027), arrhythmias (OR=4.93 (1.74-15.9); P=0.001), impaired fasting glucose/impaired glucose tolerance (OR=2.65 (1.70-4.13); P<0.0001), diabetes (OR=2.14 (1.34-3.40); P=0.0009), LVH (OR=11.9 (7.4-19.5); P<0.0001), diastolic (OR=3.32 (2.09-5.31); P<0.0001) and systolic dysfunction (OR=14.2 (6.95-32.2); P<0.0001), was higher in acromegaly. The most important predictor of LVH (t=2.4, P=0.02) and systolic dysfunction (t=-2.77, P=0.006) was disease duration and that of diastolic dysfunction was patient's age (t=-3.3, P=0.001). Patients with an estimated disease duration of >10 years had a relative risk to present cardiac complications three times higher than patients with estimated disease duration ≤5 years., Conclusions: The prevalence of different features of cardiomyopathy is 3.3-14.2 times higher in the acromegalic than in the non-acromegalic population. The major determinant of cardiomyopathy is disease duration.
- Published
- 2011
- Full Text
- View/download PDF
11. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index.
- Author
-
Colao A, Di Somma C, Savastano S, Rota F, Savanelli MC, Aimaretti G, and Lombardi G
- Subjects
- Adult, Arginine blood, Blood Pressure, Cholesterol, HDL blood, Female, Growth Hormone blood, Humans, Hypopituitarism blood, Hypopituitarism physiopathology, Male, Middle Aged, Potassium blood, Reference Values, Risk Factors, Sodium blood, Body Mass Index, Growth Hormone deficiency, Sex Characteristics, Waist Circumference
- Abstract
Objective: The objective of the study was to reevaluate the diagnostic accuracy of GH peak after GHRH plus arginine test (GHRH+ARG) according to patients' age, body mass index (BMI), and waist circumference to diagnose GH deficiency (GHD)., Outcome Measures: GH peak after GHRH+ARG and IGF-I levels reported as sd score., Subjects: Subjects included 408 controls (218 women, 190 men, aged 15-80 yr) and 374 patients with hypopituitarism (167 women, 207 men, aged 16-83 yr)., Results: In the (elderly) healthy subjects 15-25 yr old (young), 26-65 yr old (adults) and older than 65 yr, GH cutoffs were 15.6, 11.7, and 8.5 microg/liter, 11.8, 8.1, and 5.5 microg/liter, and 9.2, 6.1, and 4.0 microg/liter, respectively, in the lean, overweight, and obese subjects. Waist circumference was the best predictor of GH peak (t = -7.6, P < 0.0001) followed by BMI (t = -6.7, P < 0.0001) and age (t = -5.7, P < 0.0001). Based on the old (<9.1 microg/liter) and new GH cutoff, 286 (76.5%) and 276 (73.8%) of 374 hypopituitary patients had severe GHD. The receiving-operator characteristic analysis showed GH cutoffs in line with the third percentile or slightly higher results so that the prevalence of GHD increased to 90.1%., Conclusions: The results of the current study show that waist circumference and BMI are the strongest predictors of GH peak after GHRH+ARG followed by age. However, the old cutoff value of 9.0 microg/liter was in line with the new cutoffs in 95% of patients.
- Published
- 2009
- Full Text
- View/download PDF
12. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study.
- Author
-
Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, and Pivonello R
- Subjects
- Acromegaly metabolism, Adult, Aged, Blood Glucose analysis, Body Mass Index, Diabetes Mellitus drug therapy, Female, Glycated Hemoglobin analysis, Humans, Male, Middle Aged, Prospective Studies, Somatostatin therapeutic use, Acromegaly drug therapy, Glucose Tolerance Test, Somatostatin analogs & derivatives
- Abstract
Objective: The objective of the study was to investigate the impact of first-line somatostatin analogs (SSAs) on glucose tolerance (GT) in acromegaly., Design: The design was open and prospective., Patients: One hundred twelve patients [63 with normal GT (56.2%), 24 with impaired GT (21.4%), and 25 with diabetes (22.3%)] were treated with depot SSAs for 12 months: 54 patients (48.2%) achieved mean fasting GH levels less than 2.5 microg/liter in presence of normal IGF-I levels (controlled) during SSA., Primary Outcome Measures: Fasting glucose and glycosylated hemoglobin levels were measured., Results: At study end, 57 patients had normal GT (50.1% vs. baseline; P = 0.55), 30 had impaired fasting glucose or impaired GT (26.8%, P =0.43) and 25 had diabetes (22.3%; P = 1.0). Twenty-eight patients (25.0%), modified their GT [11 improved (9.8%), 17 worsened (15.2%)]: 90% of the patients with GT improvement achieved control of acromegaly and 89% of those having GT worsening did not (P < 0.0001). The major predictors of GT changing were disease control (t = -4.99; P < 0.0001), baseline GT (t = -2.84; P = 0.0054), and GH levels (t = 2.70; P = 0.008). Fasting glucose levels were predicted by patients' age (t = 2.74; P = 0.0071) and IGF-I levels (t = 2.14; P = 0.035). Glycosylated hemoglobin levels were predicted by disease duration (t = 3.53; P = 0.0006), GH levels (t = 2.70; P = 0.0071), and IGF-I levels (t = 2.11; P = 0.037)., Conclusions: This study showed a similar prevalence of deterioration and improvement of GT 12 months after first-line SSA treatment. Uncontrolled acromegaly during SSA treatment and abnormal GT at baseline were associated with GT worsening.
- Published
- 2009
- Full Text
- View/download PDF
13. Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study.
- Author
-
Savastano S, Di Somma C, Angrisani L, Orio F, Longobardi S, Lombardi G, and Colao A
- Subjects
- Adolescent, Adult, Body Mass Index, Energy Metabolism, Female, Humans, Insulin-Like Growth Factor I analysis, Laparoscopy, Middle Aged, Obesity, Morbid metabolism, Pilot Projects, Prospective Studies, Body Composition, Gastroplasty methods, Human Growth Hormone therapeutic use, Obesity, Morbid surgery
- Abstract
Context: The loss of lean body mass (LBM) negatively influences the outcome in bariatric surgery. Impaired GH secretion is frequent in obese patients., Objective: Our objective was to investigate if GH treatment prevents LBM loss in the early postoperative period., Design: This was an open, prospective, randomized, and controlled study., Patients: A total of 24 women (body mass index: 44.4 +/- 7.6 kg/m(2), aged 36.8 +/- 11.7 yr) undergoing laparoscopic-adjustable silicone gastric banding (LASGB) and with GH deficiency after LASGB was included in the study., Treatment Protocol: Group A (n = 12) included a standardized diet regimen and exercise program plus recombinant human GH (0.5 +/- 0.13 mg every day), and group B (n = 12) included a standardized diet regimen and exercise program. The follow-up duration was 6 months., Results: The excess of body weight loss did not differ between groups A and B after 3 and 6 months. At 3 months, LBM loss was lower (P < 0.0001) and fat mass (FM) loss was higher (P = 0.02) in group A than group B. At 3 and 6 months, appendicular skeletal muscle mass loss was lower (P = 0.000) in group A than group B. At 3 (P = 0.0003 and 0.0005, respectively) and 6 months (P < 0.0001 and 0.0002, respectively), the percent changes of FM and lean body mass were significantly higher in group A than group B. In both groups fasting and postglucose area under the plasma concentration-time curve insulin significantly reduced. The homeostasis model assessment of insulin and insulin sensitivity indexes and total to high-density lipoprotein cholesterol ratio improved only in group A., Conclusions: GH treatment for 6 months after LASGB reduces loss in LBM and appendicular skeletal muscle mass during a standardized program of low-calorie diet and physical exercise program, with improvement of lipid profile and without a deterioration of glucose tolerance.
- Published
- 2009
- Full Text
- View/download PDF
14. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects.
- Author
-
Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G, and Savastano S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose metabolism, Blood Pressure, Cross-Sectional Studies, Diabetes Mellitus epidemiology, Diabetes Mellitus metabolism, Female, Homeostasis, Humans, Hypercholesterolemia epidemiology, Hypercholesterolemia metabolism, Hypertriglyceridemia epidemiology, Hypertriglyceridemia metabolism, Male, Middle Aged, Prevalence, Risk Factors, Glucose Intolerance epidemiology, Glucose Intolerance metabolism, Hypertension epidemiology, Hypertension metabolism, Insulin-Like Growth Factor I metabolism
- Abstract
Background: In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality., Objective: To investigate the relationships between IGF1 levels, blood pressure (BP), and glucose tolerance (GT)., Subjects: Four-hundred and four subjects (200 men aged 18-80 years)., Exclusion Criteria: personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids (>2 weeks), estrogens, or testosterone (>12 weeks); smoking of >15 cigarettes/day and alcohol abuse (>3 glasses of wine/day)., Results: Two hundred and ninety-six had normal BP (73.3%), 86 had mild (21.3%), and 22 had severe (5.4%) hypertension; 322 had normal GT (NGT (79.7%)), 53 had impaired glucose tolerance (IGT (13.1%)), 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF1 levels (0.11+/-0.94 SDS) than those with mild (-0.62+/-1.16 SDS, P<0.0001) or severe (-1.01+/-1.07 SDS, P<0.0001) hypertension. IGF1 SDS (t=-3.41, P=0.001) independently predicted systolic and diastolic BP (t=-2.77, P=0.006) values. NGT subjects had significantly higher IGF1 levels (0.13+/-0.90 SDS) than those with IGT (-0.86+/-1.14 SDS, P<0.0001) or diabetes mellitus (-1.31+/-1.13 SDS, P<0.0001). IGF1 SDS independently predicted fasting glucose (t=-3.49, P=0.0005) and homeostatic model assessment (HOMA)-R (t=-2.15, P=0.033) but not insulin (t=-1.92, P=0.055) and HOMA-beta (t=-0.19, P=0.85)., Conclusion: IGF1 levels in the low normal range are associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
- Published
- 2008
- Full Text
- View/download PDF
15. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency.
- Author
-
Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC, and Lombardi G
- Subjects
- Adult, Algorithms, Atherosclerosis complications, Atherosclerosis drug therapy, Atherosclerosis pathology, Carotid Artery, Common diagnostic imaging, Carotid Artery, Common pathology, Dwarfism, Pituitary complications, Dwarfism, Pituitary pathology, Follow-Up Studies, Hormone Replacement Therapy, Humans, Hypopituitarism complications, Hypopituitarism drug therapy, Hypopituitarism pathology, Male, Metabolic Syndrome complications, Metabolic Syndrome epidemiology, Middle Aged, Prevalence, Time Factors, Tunica Media diagnostic imaging, Tunica Media pathology, Ultrasonography, Atherosclerosis epidemiology, Dwarfism, Pituitary drug therapy, Human Growth Hormone deficiency, Human Growth Hormone therapeutic use
- Abstract
Background: Severe GH deficiency (GHD) is associated with, increased cardiovascular risk and intima-media thickness (IMT) at major arteries., Objective: The objective of the study was to investigate the 5-yr effects of GH replacement on common carotid IMT and insulin resistance syndrome (IRS) (at least two of the following: triglycerides levels > or = 1.7 mmol/liter, high-density lipoprotein-cholesterol levels < or = 1.0 mmol/liter, blood pressure above 130/85 mm Hg, fasting glucose 6.1-7 or 2 hr after glucose 7.7-11.1 mmol/liter)., Design: This was an interventional, open, prospective, controlled study., Patients: Patients included 35 men with severe GHD and 35 age-matched healthy men as controls., Intervention: All patients received standard replacement therapy; GH replacement was added in 22 patients (group A) and refused by 13 others (group B)., Measurements: Five-year changes in IMT and IRS prevalence were measured., Results: At baseline, IMT was higher in the patients with (P < 0.001) and without IRS (P = 0.004) than in controls. Eighteen patients (51.4%) and two controls (5.7%; P < 0.0001) had IRS. At study end, use of lipid-lowering drugs (92.3, vs. 13.6 and 34.3%, P < 0.0001), glucose-lowering drugs (69.2 vs. 31.4 and 22.7%; P = 0.016), and antihypertensive drugs (61.5 vs. 20.0 and 4.5%; P < 0.0001) was higher in group B patients than controls and group A patients. IGF-I levels normalized in all group A patients and remained lower than -1 sd score in 77% of group B patients. IMT significantly decreased only in group A and significantly increased in controls and nonsignificantly in group B patients. IRS prevalence significantly reduced only in group A patients., Conclusions: Severely hypopituitary GHD men have more frequently increased IMT at common carotid arteries and IRS than controls. After 5 years, only in GH replaced patients, IMT and prevalence of IRS decreased.
- Published
- 2008
- Full Text
- View/download PDF
16. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.
- Author
-
Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, and Lombardi G
- Subjects
- Acromegaly drug therapy, Acromegaly etiology, Acromegaly pathology, Adenoma complications, Adenoma pathology, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal administration & dosage, Delayed-Action Preparations, Female, Follow-Up Studies, Growth Hormone-Secreting Pituitary Adenoma complications, Growth Hormone-Secreting Pituitary Adenoma pathology, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Time Factors, Treatment Outcome, Adenoma diagnosis, Adenoma drug therapy, Growth Hormone-Secreting Pituitary Adenoma diagnosis, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Octreotide administration & dosage, Tumor Burden drug effects
- Abstract
Objective: The objective of the study was to evaluate whether tumor shrinkage or GH and IGF-I levels achieved after 3 months predicted tumor shrinkage after 12 months of octreotide-long-acting release (LAR) treatment., Patients: Patients included 67 patients with de novo acromegaly (33 women, 34 men; aged 20-82 yr) receiving LAR at a dose of 20 mg every 28 d for 3 months. Final LAR dose was 10 mg every 28 d in 4, 30 mg every 28 d in 39, 20 mg every 28 d in 24 patients., Design: The design of the study was analytical, observational, open, and retrospective., Outcome Measures: Percent change in GH and IGF-I levels and tumor volume after 3 and 12 months of therapy was measured. Stepwise regression and receiving-operator characteristics analysis were used to calculate the optimal cutoff to predict 12 months tumor shrinkage at 12 months., Results: The percent tumor shrinkage after 12 months was significantly correlated with GH, IGF-I, and tumor volume at 3 months and with the dose of LAR administered between 3 and 12 months. There was no correlation with gender, age, baseline GH levels and tumor volume. In a stepwise regression analysis, percent tumor shrinkage after 3 months was the best predictor of tumor shrinkage after 12 months (t = 5.92; P < 0.0001), followed by GH levels after 3 months (t = 2.86; P = 0.0056). To predict 50% or greater tumor shrinkage after 12 months, the best cutoff point of tumor shrinkage at 3 months was 22.1% [sensitivity (95% confidence interval) = 85.5% (71.2-95.4); specificity = 83.3% (65.3-94.3)], whereas that of GH levels after 3 months was 7.8 microg/liter [sensitivity = 70.3% (53.0-84.1); specificity = 93.3% (79.0-99.0)]., Conclusion: Tumor shrinkage achieved after 3 months of LAR treatment at 20 mg/28 d predicted tumor shrinkage at 12 months, provided that dosages were changed according to individual patients requirement.
- Published
- 2008
- Full Text
- View/download PDF
17. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.
- Author
-
Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, and Lombardi G
- Subjects
- Acromegaly blood, Adult, Aged, Aged, 80 and over, Delayed-Action Preparations, Dose-Response Relationship, Drug, Female, Growth Hormone blood, Humans, Insulin-Like Growth Factor I metabolism, Male, Middle Aged, Octreotide chemistry, Prospective Studies, Acromegaly drug therapy, Octreotide administration & dosage
- Abstract
Objective: To evaluate the efficacy of dose escalation of Octreotide-long-acting repeatable (LAR) up to 40 mg/month we studied 56 newly diagnosed patients with acromegaly (24 women, 32 men; age 20-82 years)., Design: Analytical, observational, open and prospective., Methods: Three months after LAR treatment beginning with a dose of 20 mg /q28d (every 28 days), 24 patients maintained the same dose (Group A), while 32 required a dose of 30 mg/q28d (Group B). The dose was further increased to 40 mg/q28d in 17 out of the 32 patients of Group B for another 12 months (Group C)., Results: After 24 months, serum GH and IGF-I levels decreased by 93.1 +/- 8.6% (95% confidence limit (CL) 90.8-95.4%) and 62.7 +/- 13.4% (95% CL 59.1-66.3%) respectively. Control of GH and IGF-I levels was achieved in 45 patients (80.3%). Tumor shrinkage after 12 months was 49.8 +/- 23%; the relative tumor shrinkage during the second 12 months of treatment was 35.3 +/- 13.1% and overall tumor volume was 68.1 +/- 16.5% (95% CL 63.7-72.5%). Glucose tolerance impaired in eight patients (14.3%): four in Group A and four in Group C (16.7% vs 36.4%, P=0.39). The final dose was predicted by the patient's age at diagnosis (t=-2.2; P=0.032) and baseline tumor volume (t=2.1; P=0.043)., Conclusion: An increase of the LAR dose up to 40 mg/q28d in patients resistant to 30 mg/q28d is followed by greater suppression of GH and IGF-I levels and tumor shrinkage without further significant impairment of glucose tolerance when compared with lower doses. These results suggest that a new dosage schedule of 40 mg every 28 days is applied in patients with acromegaly mostly of young age and with bigger tumors who are likely to be poorly responsive to standard doses of Octreotide-LAR.
- Published
- 2007
- Full Text
- View/download PDF
18. The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis.
- Author
-
Colao A, Di Somma C, Spiezia S, Rota F, Pivonello R, Savastano S, and Lombardi G
- Subjects
- Adult, Arginine pharmacology, Carotid Artery, Common pathology, Case-Control Studies, Cholesterol, HDL blood, Female, Follow-Up Studies, Growth Hormone-Releasing Hormone pharmacology, Human Growth Hormone metabolism, Humans, Male, Middle Aged, Prospective Studies, Risk, Tunica Intima pathology, Atherosclerosis etiology, Cardiovascular Diseases etiology, Human Growth Hormone deficiency
- Abstract
Background: Partial GH deficiency (GHD) in adults is poorly studied., Objective: The objective of the study was to investigate the natural history and clinical implications of partial GHD., Study Design: This was an analytical, observational, prospective, case-control study., Patients: Twenty-seven hypopituitary patients (15 women, ages 20-60 yr) and 27 controls participated in the study., Main Outcome Measures: Measures included GH peak after GHRH plus arginine [(GHRH+ARG), measured by immunoradiometric assay]; IGF-I (measured after ethanol extraction) z-sd score (SDS); glucose, insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels; and common carotid arteries intima-media thickness (IMT) measured periodically., Results: At study entry, partial GHD patients had significantly lower IGF-I and HDL-cholesterol levels and homeostasis model assessment index than controls. During the 60 months of median follow-up, 11 patients had severe GHD (40.7%), seven normalized their GH response (25.9%), and nine showed persistently partial GHD (33.3%). Patients with developed severe GHD at baseline had similar age and body mass index and lower GH peak (11.5 +/- 1.8 vs. 14.3 +/- 1.5 and 12.8 +/- 1.1 microg/liter, P = 0.008) and IGF-I SDS (-0.88 +/- 0.48 vs. 0.15 +/- 0.58 and -0.42 +/- 0.78; P = 0.01) than the patients with normal GH secretion or partial GHD. Severe GHD was accompanied by decreased IGF-I SDS and increased total to HDL cholesterol ratio, triglycerides, homeostasis model assessment index, and carotid intima-media thickness; normalization of GH secretion was accompanied by increased IGF-I SDS. By receiving-operator characteristic analysis, predictors of severe GHD were a baseline GH peak after GHRH+ARG of 11.5 microg/liter (sensitivity 64%, specificity 94%) and a baseline IGF-I SDS of -0.28 (sensitivity 91%, specificity 63%)., Conclusions: Of 27 patients with partial GHD after pituitary surgery, 40.7% developed severe GHD and 25.9% normalized their GH response. With the assay used, changes in the GH peak response to GHRH+ARG were accompanied by changes in the IGF-I SDS, metabolic profile, and carotid IMT. A peak GH of 11.5 microg/liter or less and IGF-I SDS -0.28 or less were highly predictive of delayed deterioration of GH secretion.
- Published
- 2006
- Full Text
- View/download PDF
19. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.
- Author
-
Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, and Colao A
- Subjects
- Area Under Curve, Cardiovascular Diseases etiology, Endothelin-1 blood, Endothelium, Vascular physiopathology, Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome complications, Polycystic Ovary Syndrome metabolism, Polycystic Ovary Syndrome pathology, Prospective Studies, Endothelium, Vascular pathology, Hypoglycemic Agents therapeutic use, Metformin therapeutic use, Polycystic Ovary Syndrome drug therapy
- Abstract
Context: Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients., Objective: The objective of this study was to evaluate the effects of 6 months of metformin administration on endothelial structure and function in women with PCOS., Design: This was a prospective, baseline-controlled, clinical study., Setting: The study was performed at University Federico II (Naples, Italy)., Patients: Thirty young normal-weight women with PCOS without additional metabolic or cardiovascular diseases were studied., Interventions: Metformin (850 mg daily) was administered for 6 months., Mean Outcome Measures: The main outcome measures were complete hormonal profile, including total testosterone, SHBG, dehydroepiandrosterone sulfate, prolactin, and gonadotropin levels; serum insulin and glucose levels during a 75-g 2-h oral glucose tolerance test; plasma endothelin-1 concentrations (picomoles per liter +/- sd); serum lipid profile; brachial artery baseline diameter (millimeters +/- sd), diameter after reactive hyperemia (millimeters +/- sd), and flow-mediated dilation (percentage +/- sd); and the intima media thickness (millimeters +/- sd) on both common carotid arteries., Results: After treatment, SHBG levels and the free androgen index changed significantly (P < 0.001). High-density lipoproteins and the area under curve for glucose/area under curve for insulin ratio also significantly (P < 0.001) increased, whereas low-density lipoproteins and plasma endothelin-1 levels were significantly (P < 0.001) reduced. No other change was found in any of the biochemical parameters evaluated. A significant difference was observed in brachial artery baseline diameter (3.24 +/- 0.30 vs. 3.0 +/- 0.30), flow-mediated dilation (14.30 +/- 1.90 vs. 15.70 +/- 1.50) (P < 0.01, each), diameter after reactive hyperemia (3.70 +/- 0.30 vs. 3.55 +/- 0.10) (P < 0.05), and intima media thickness (0.53 +/- 0.09 vs. 0.40 +/- 0.07) (P < 0.001) after metformin treatment in comparison with baseline values., Conclusions: A 6-month course of metformin improves endothelial structure and function in young, normal-weight women with PCOS.
- Published
- 2005
- Full Text
- View/download PDF
20. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
- Author
-
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, and Fenzi G
- Subjects
- Female, Graves Disease etiology, Humans, Middle Aged, Radionuclide Imaging, Receptors, Thyrotropin analysis, Receptors, Thyrotropin physiology, Recombinant Proteins pharmacology, Graves Disease diagnostic imaging, Indium Radioisotopes, Octreotide analogs & derivatives, Octreotide pharmacokinetics, Orbit metabolism, Pentetic Acid analogs & derivatives, Pentetic Acid pharmacokinetics, Radiopharmaceuticals pharmacokinetics, Thyrotropin pharmacology
- Abstract
Here we describe the case of a 60-yr-old nonsmoking woman with a history of Graves' disease associated with papillary thyroid carcinoma. After tumor removal, during the diagnostic follow-up for thyroid cancer, there was evidence of severe Graves' ophthalmopathy (GO) successfully treated with iv glucocorticoids. After this treatment, GO entered inactive status. The patient was then reevaluated for thyroid cancer with human recombinant TSH (rTSH). Orbital [111In-diethylenetriamine-pentacetic acid (DTPA)-D-phe1]octreotide scan was also performed, and results were negative. Shortly after rTSH administration, a moderate and transient pain behind the eye globes at rest and during eye movement was reported, with an increase in the activity score but without further GO progression. Twenty-four hours after rTSH administration, the patient was submitted to a second [111In-DTPA-D-phe1]octreotide scan, revealing significant orbital uptake, likely related to rapid accumulation of activated lymphocytes with inflammatory cytokines or fibroblasts expressing somatostatin receptors in the orbital tissue or interstitial edema due to the inflammation process. At last follow-up performed after 1 yr, there was no evidence of active thyroid cancer or changes in GO severity and/or activity, and orbital [111In-DTPA-D-phe1]octreotide uptake was negative. This case further supports the involvement of TSH receptor in the pathogenesis of GO. It also confirms the usefulness of orbital [111In-DTPA-D-phe1]octreotide scan to evaluate GO activity.
- Published
- 2005
- Full Text
- View/download PDF
21. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome.
- Author
-
Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanovà L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, and Lombardi G
- Subjects
- Adult, Biomarkers, Chronic Disease, Female, Humans, Polycystic Ovary Syndrome complications, Risk, Cardiovascular Diseases etiology, Inflammation diagnosis, Leukocyte Count, Polycystic Ovary Syndrome blood
- Abstract
White blood cell (WBC) count is a known risk factor for atherosclerotic vascular disease in adult women. Polycystic ovary syndrome (PCOS) is potentially a risk factor for atherosclerosis and cardiovascular disease. The aim of the present study was to investigate leukocyte count in PCOS. One hundred and fifty PCOS women matched for age and body mass index with 150 healthy women were enrolled. WBC count, C-reactive protein, and a complete anthropometrical, metabolic, and hormonal evaluation were performed in both groups. Serum insulin, glucose level, and lipid profile were also measured in each subject. WBC count was significantly higher (P < 0.0001) in PCOS with (interquartile range in parentheses) 7260 (393) cells/mm(3), compared with controls with 5220 (210) cells/mm(3). C-reactive protein levels were significantly increased (P < 0.0001) in PCOS with 2 (1) mg/liter compared with healthy women with 0.7 (0.8) mg/liter. In both groups, there was a significant (P < 0.0001) linear correlation between WBC count and homeostasis model assessment score (PCOS, r = 0.94; controls, r = 0.91). Multiple linear regression analysis showed that other hormone levels are not predictors of leukocyte count both in PCOS and control women. In conclusion, our data demonstrate that PCOS women have an increased WBC count that correlates with homeostasis model assessment values.
- Published
- 2005
- Full Text
- View/download PDF
22. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study.
- Author
-
Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, and Lombardi G
- Subjects
- Adult, Aged, Arginine, Case-Control Studies, Coronary Circulation, Diastole, Exercise Test, Female, Growth Hormone-Releasing Hormone, Heart Diseases diagnosis, Hemodynamics, Humans, Linear Models, Male, Metabolic Diseases diagnosis, Middle Aged, Severity of Illness Index, Stroke Volume, Systole, Ventricular Function, Left, Heart Diseases etiology, Heart Diseases physiopathology, Human Growth Hormone deficiency, Hypopituitarism complications, Metabolic Diseases etiology, Metabolic Diseases physiopathology
- Abstract
In 100 patients with hypopituitarism and 80 sex- and age-matched healthy subjects, we correlated the severity of cardiac impairment to the severity of GH deficiency (GHD). By the GH peak after arginine plus GHRH test (normal > 16.5 microg/liter), the patients were classified as severe GHD (n = 56), partial GHD (n = 27), and non-GHD (n = 17). Compared with controls, decreased left ventricular ejection fraction at rest was found only in severe GHD patients (55.0 +/- 8.8 vs. 63.4 +/- 4.5%, P < 0.001); decreased left ventricular ejection fraction response on effort in severe (-4.6 +/- 17.4 vs. 15.2 +/- 9.1%, P < 0.001) and partial GHD patients (3.6 +/- 6.6 vs. 14.6 +/- 8.3%, P < 0.001); decreased diastolic filling at rest in severe (2.53 +/- 0.68 vs. 3.01 +/- 0.48 end-diastolic volume per second, P < 0.001) and partial GHD (2.61 +/- 0.45 vs. 2.89 +/- 0.54 end-diastolic volume per second, P = 0.004) patients; and decreased exercise duration and capacity in all the patient groups. A normal systolic performance on effort was found in 21.4% of severe GHD, 55.6% of partial GHD, all non-GHD, and 93.7% of controls. A normal diastolic filling at rest was found in 57.1% of severe GHD, 74.1% of partial GHD, 76.5% of non-GHD, and 90% of controls. In conclusion, cardiac performance is correlated with the GH status because significant impairment was found in patients with severe and partial GHD but not in non-GHD hypopituitary patients.
- Published
- 2004
- Full Text
- View/download PDF
23. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome.
- Author
-
Orio F Jr, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, Savastano S, Zullo F, Colao A, Vettor R, and Lombardi G
- Subjects
- Adiponectin, Adult, Blood Glucose, Body Mass Index, Female, Genotype, Humans, Insulin blood, Lipids blood, Polymorphism, Genetic, Intercellular Signaling Peptides and Proteins metabolism, PPAR gamma genetics, Polycystic Ovary Syndrome blood, Polycystic Ovary Syndrome genetics
- Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine metabolic diseases and is characterized by obesity in approximately 50% of those affected. Adiponectin is an adipocyte-derived protein that possesses an antiatherosclerotic action and improves insulin sensitivity. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) regulates the transcription of several adipocyte-specific genes. The aim of this study was to investigate the putative influence of the PPAR-gamma gene Pro12Ala polymorphism on the adiponectin levels in PCOS and healthy women. One hundred twenty women with PCOS and 120 healthy women whose ages and body mass indexes matched those of the PCOS patients were investigated. The genetic analysis of PPAR-gamma gene Pro12Ala polymorphism was performed by restriction fragment of polymorphisms. Serum adiponectin levels were evaluated, and the homeostasis model assessment score was also calculated. No subject was homozygous for the Ala12 allele of the PPAR-gamma gene. No significant differences in body mass index, plasma glucose and lipid levels, and homeostasis model assessment scores were observed between and within genotype groups in PCOS and control women. No significant differences in serum adiponectin concentrations were observed between and within genotype groups in PCOS and control women. In conclusion, our results confirm that adiponectin concentrations are similar in PCOS and controls and demonstrate no effect of the PPAR-gamma gene Pro12Ala polymorphism on serum adiponectin levels.
- Published
- 2004
- Full Text
- View/download PDF
24. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome.
- Author
-
Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, Savastano S, Zullo F, Colao A, and Lombardi G
- Subjects
- Adult, Alleles, Body Mass Index, Case-Control Studies, Cytosine, Female, Gene Frequency, Humans, Leptin blood, Polycystic Ovary Syndrome blood, Polycystic Ovary Syndrome pathology, Thymine, Exons genetics, Polycystic Ovary Syndrome genetics, Polymorphism, Genetic genetics, Receptors, Cytoplasmic and Nuclear genetics, Transcription Factors genetics
- Abstract
Obesity affects about 44% of women with polycystic ovary syndrome (PCOS). Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is one of the genes involved in the differentiation of adipose tissue. In an attempt to shed light on the high percentage of obesity in PCOS, we examined polymorphisms at exons 6 and 2 of the PPAR-gamma gene in 100 PCOS patients and in 100 healthy controls matched for age and body mass index (BMI). The T allele frequency of exon 6 was significantly higher (P < 0.05) in PCOS patients compared with control women. In addition, the BMI and leptin levels were significantly higher (P < 0.05) in PCOS patients carrying the C-->T substitution than in controls. There was no significant difference in leptin levels after normalization for BMI. The Pro(12)Ala polymorphism at exon 2 was unrelated to BMI and/or leptin levels in PCOS women. In conclusion, the higher frequency of the C-->T substitution in exon 6 of the PPAR-gamma gene in PCOS women suggests that it plays a role in the complex pathogenetic mechanism of obesity in PCOS, whereas the Pro(12)Ala polymorphism does not seem to affect BMI in PCOS women.
- Published
- 2003
- Full Text
- View/download PDF
25. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome.
- Author
-
Orio F Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, Labella D, Russo T, Zullo F, and Lombardi G
- Subjects
- Adolescent, Adult, Blood Glucose, Female, Genotype, Humans, Insulin blood, Insulin Resistance, Methylenetetrahydrofolate Reductase (NADPH2), Oxidoreductases Acting on CH-NH Group Donors metabolism, Homocysteine blood, Oxidoreductases Acting on CH-NH Group Donors genetics, Polycystic Ovary Syndrome blood, Polycystic Ovary Syndrome genetics, Polymorphism, Single Nucleotide
- Abstract
The aim of this study was to investigate the homocysteine (Hcy) levels and the C677T polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR), a crucial factor of the Hcy metabolism in young women with polycystic ovary syndrome (PCOS). Seventy young women with PCOS and another 70 healthy women with low folate intake were enrolled. Cases and controls were matched for age, body mass index, and allele frequency. Hcy, vitamin B(12), and folate levels were measured, and a genetic analysis of 5,10-MTHFR at nucleotide 677 was performed in all subjects. No difference in mean Hcy levels was observed between PCOS women in comparison to the control group. Considering the different MTHFR polymorphism, no significant difference was found in serum Hcy levels between subjects with PCOS and controls showing CC (10.4 +/- 3.1 vs. 9.7 +/- 2.9 micromol/liter +/- SD) and CT genotypes (10.9 +/- 3.8 vs. 11.0 +/- 3.2 micromol/liter +/- SD). In subjects with a TT homozygous state, a significant (P < 0.05) difference was observed between PCOS and control women (11.5 +/- 3.9 vs. 22.0 +/- 7.8 micromol/liter +/- SD). In conclusion, our data show that in PCOS women, the serum Hcy levels are normal, and the C677T polymorphism of MTHFR does not influence the Hcy levels like in controls.
- Published
- 2003
- Full Text
- View/download PDF
26. Markers of potential coeliac disease in patients with Hashimoto's thyroiditis.
- Author
-
Valentino R, Savastano S, Maglio M, Paparo F, Ferrara F, Dorato M, Lombardi G, and Troncone R
- Subjects
- Adolescent, Adult, Aged, Biomarkers, Biopsy, Celiac Disease immunology, Celiac Disease pathology, Female, HLA Antigens analysis, HLA Antigens classification, Humans, Immunohistochemistry, Jejunum immunology, Jejunum pathology, Male, Middle Aged, Celiac Disease etiology, Thyroiditis, Autoimmune complications, Thyroiditis, Autoimmune immunology
- Abstract
Objective: Coeliac disease (CD) is associated with autoimmune thyroid disease. Gluten sensitivity represents a spectrum, with at one end cases with severe gluten-dependent enteropathy, and at the other subjects with minor signs of deranged mucosal immune response. The aim of this paper was to look for signs of minor small bowel injury and immunohistochemical markers of gluten sensitivity in a group of patients with Hashimoto's disease., Subjects and Methods: Fourteen patients with Hashimoto's thyroiditis without serological evidence of CD underwent immunohistochemical analysis of jejunal biopsies., Results: In 6/14 cases (43%) an increased density of gammadelta T cell receptor bearing intra-epithelial lymphocytes was found. In 6/14 (43%) signs of mucosal T cell activation (presence of interleukin 2 (IL2) receptor (CD25) on lamina propria T cells and/or expression of human lymphocyte antigen (HLA)-DR molecules on crypt epithelial cells) were noted. In 4 out of 6 such cases, HLA haplotypes were described in association with CD., Conclusion: A significant proportion of patients with Hashimoto's thyroiditis present signs of 'potential' CD and of activated mucosal T cell immunity. The gluten dependence of such findings remains to be ascertained.
- Published
- 2002
- Full Text
- View/download PDF
27. The influence of intense ballet training on trabecular bone mass, hormone status, and gonadotropin structure in young women.
- Author
-
Valentino R, Savastano S, Tommaselli AP, D'Amore G, Dorato M, and Lombardi G
- Subjects
- Adult, Cross-Sectional Studies, Energy Intake, Female, Follicle Stimulating Hormone blood, Gonadotropin-Releasing Hormone pharmacology, Humans, Luteinizing Hormone blood, Bone Density, Exercise
- Abstract
A cross-sectional study on young dancers and exdancers was performed to evaluate the effects of intense weight-bearing exercise and dietary restriction, started during puberty, on bone mineral density (BMD), menarche age, menstrual function, and gonadotropin structure. Twenty current dancers (group 1) and 9 exdancers (group 2) were compared with a control group of 30 age-matched, regularly cycling women. Body weight, body mass index, total daily caloric intake, and nutritional markers were significantly lower (P < 0.05) in groups 1 and 2 than in controls. Using Quantitative Computed Tomography for the BMD evaluation, 12 dancers and 5 exdancers had Z-scores less than 2.5 SD below the mean of the controls; whereas, in 6 dancers and in 2 exdancers, BMD was between 1 and 2.5 SD. Groups 1 and 2 had a delay of menarche, which correlated positively with years of dance before menarche (r = 0.8; P < 0.001). Dancers had low levels and altered structure of circulating gonadotropins, which improved after GnRH stimulation. In conclusion, ballet training performed by dancers during puberty, dietary restriction, and low body mass index can all be associated with reduction in BMD and altered gonadotropin isoforms, with subsequent delay of menarche, menstrual dysfunctions, and insufficient peak bone mass. A longitudinal study must be conducted to confirm the persistence of low lumbar spine bone density in adult age.
- Published
- 2001
- Full Text
- View/download PDF
28. Changes in the glycosylation pattern of circulating gonadotropins after acute administration of gonadotropin-releasing hormone in patients with anorexia nervosa.
- Author
-
Savastano S, Tommaselli AP, Valentino R, Luciano A, Gigante M, Randazzo G, Contaldo F, Scalfi L, and Lombardi G
- Subjects
- Adolescent, Adult, Concanavalin A metabolism, Female, Follicle Stimulating Hormone metabolism, Food, Glycosylation, Humans, Luteinizing Hormone metabolism, Reference Values, Time Factors, Anorexia Nervosa blood, Anorexia Nervosa drug therapy, Follicle Stimulating Hormone blood, Gonadotropin-Releasing Hormone therapeutic use, Luteinizing Hormone blood
- Abstract
To study the involvement of gonadotropin-releasing hormone (GnRH) in glycosylation of circulating gonadotropin isoforms in anorexia nervosa (AN), 14 amenorrhoic patients with AN, 14 age-matched volunteers in early follicular phase, and five normal-weight re-fed patients with AN were investigated under baseline conditions and after acute administration of GnRH. Plasma gonadotropins were assayed using IRMA before and after concanavalin A affinity chromatography. Baseline plasma gonadotropin levels were lower for both AN and re-fed AN patients than in controls (P<0.005). The increase in FSH and LH after GnRH administration was lower than in controls for AN (P<0.005) and re-fed AN (P<0.005 and P<0.05 respectively) patients. Percentages of total gonadotropin not bound to concanavalin A (complex carbohydrate chains) under baseline conditions were higher in patients with AN than in controls (P<0.005) but decreased after GnRH administration (P<0.001). In re-fed AN patients, the percentage of unbound FSH was higher than in controls (P<0.05), and decreased after GnRH administration (P<0.001), whereas the percentages of unbound LH were not significantly different from controls either before or after GnRH administration. These data suggest that: (a) the acute administration of GnRH induces quantitative and qualitative changes in circulating gonadotropin isoforms in both normal controls and AN patients; (b) during recovery the LH response in re-fed AN patients is associated with a glycosylation pattern that is the same as that for controls.
- Published
- 1998
- Full Text
- View/download PDF
29. Usefulness of 123I-metaiodobenzylguanidine (MIBG) scintiscan in the diagnosis of juxta-adrenal schwannoma.
- Author
-
Tommaselli AP, Valentino R, Rossi R, Savastano S, Luciano A, Battista C, Troncone G, and Lombardi G
- Subjects
- 3-Iodobenzylguanidine, Adrenal Gland Neoplasms pathology, Adult, Humans, Male, Neurilemmoma pathology, Radionuclide Imaging, Tomography, X-Ray Computed, Adrenal Gland Neoplasms diagnostic imaging, Contrast Media, Iodine Radioisotopes, Iodobenzenes, Neurilemmoma diagnostic imaging
- Abstract
The adrenal scintiscan with 123I-metaiodobenzylguanidine (MIBG), a reliable morphofunctional technique to evaluate catecholamine turnover in adrenal tumors, can be a useful method to investigate adrenal incidentalomas with arterial hypertension. A male patient, 44 yr old with diabetes, unstable arterial hypertension, and sudden paroxysms of tachycardia is described. The presence of a disomogeneous right juxta-adrenal neoplasm with calcifications was evidenced with ultrasound tomography and confirmed by computerized tomography (CT) scan. Adrenal 123I-MIBG scintiscan revealed a unilateral uptake at level of the right juxta-adrenal region, sized similarly to the neoplasm previously evidence by CT scan. Histological findings of the surgically removed neoplasm were consistent with an ancient schwannoma. Apart from pheochromocytomas, the MIBG uptake is commonly reported in neuroblastomas. In neuroblastoma, a bidirectional process of transdifferentiation has been previously reported in vitro between two coexistent cells: cells with specific uptake system for norepinephrine, with 123I-MIBG uptake capability, and cells oriented toward schwann/melanocytic line. The evidence of in vivo MIBG uptake in our schwannoma may be caused by the same possible phenotypic interconversion of above mentioned cell types. In conclusion, the presence of adrenal tumors with MIBG uptake capability, apart from pheochromocytomas, neuroblastomas, ganglioneuroblastomas, and ganglioneuromas, must be considered in the diagnosis of adrenal tumors.
- Published
- 1996
- Full Text
- View/download PDF
30. Altered glycosylation of pituitary gonadotropins in anorexia nervosa: an alternative explanation for amenorrhea.
- Author
-
Tommaselli AP, Valentino R, Savastano S, Randazzo G, Scalfi L, Contaldo F, Dorato M, and Lombardi G
- Subjects
- Adolescent, Adult, Amenorrhea blood, Anorexia Nervosa blood, Chromatography, Affinity, Concanavalin A, Estradiol blood, Female, Follicle Stimulating Hormone blood, Glycosylation, Gonadotropins analysis, Humans, Immunoradiometric Assay, Luteinizing Hormone blood, Pituitary Gland chemistry, Pituitary Gland metabolism, Radioimmunoassay, Sex Hormone-Binding Globulin analysis, Amenorrhea etiology, Amenorrhea metabolism, Anorexia Nervosa complications, Anorexia Nervosa metabolism, Gonadotropins metabolism
- Abstract
To investigate the relevance of glycoprotein polymorphism to gonadotropin bioactivity in vivo, plasma follicle-stimulating hormone (FSH) and luteinizing hormone (LH), 17 beta-estradiol (E2), testosterone and sex hormone binding globulin (SHBG) levels in 17 amenorrheic women affected with anorexia nervosa (14-29 years) and 10 age-matched normally cycling women were evaluated. Plasma FSH and LH levels were assayed using radioimmunoassay (RIA) and immunoradiometric assay (IRMA) methods, before and after concanavalin A-Sepharose (Con A) affinity chromatography. Significant RIA-IRMA differences in FSH and LH plasma values were present only in women with anorexia nervosa (p < 0.005). Moreover, in these patients both FSH and LH showed a reduced binding to the Con A, expressed as a percentage of unbound, suggesting altered glycosylation of these moieties. In conclusion, these findings hypothesize the involvement of glycosylation polymorphism in RIA-IRMA differences; support the usefulness of both RIA and IRMA methods in FSH and LH evaluation, before and after Con A chromatography; and suggest a new pathogenetic pathway to explain amenorrhea in anorexia nervosa.
- Published
- 1995
- Full Text
- View/download PDF
31. Percutaneous computed tomography-guided ethanol injection in aldosterone-producing adrenocortical adenoma.
- Author
-
Rossi R, Savastano S, Tommaselli AP, Valentino R, Iaccarino V, Tauchmanova L, Luciano A, Gigante M, and Lombardi G
- Subjects
- Adrenal Cortex Neoplasms blood, Adrenal Cortex Neoplasms diagnostic imaging, Adrenal Cortex Neoplasms metabolism, Adrenocortical Adenoma blood, Adrenocortical Adenoma diagnostic imaging, Adrenocortical Adenoma metabolism, Adult, Aldosterone blood, Humans, Injections, Intralesional, Male, Adrenal Cortex Neoplasms drug therapy, Adrenocortical Adenoma drug therapy, Aldosterone metabolism, Ethanol administration & dosage, Tomography, X-Ray Computed
- Abstract
The feasibility, safety and effectiveness of percutaneous computed tomography-guided ethanol injection (PEI-CT) was investigated in a patient affected by aldosterone-producing adenoma (APA). A 42-year-old male patient with typical features of hyperaldosteronism presented a solitary left adrenal adenoma measuring 2 cm, with a normal contralateral gland, evidenced by both CT scan and adrenal [75Se-19]-nor-cholesterol scintigraphy. After normalization of potassium plasma levels, 4 ml of sterile 95% ethanol with 0.5 ml of 80% iothalamate sodium was injected. The procedure was completed in about 30 min. No severe pain or local complication was noted. Five hours after PEI, a fourfold and a twofold increase in aldosterone and cortisol plasma levels were observed, respectively. After 11 days on a normal sodium and potassium diet, normal potassium plasma levels and reduced aldosterone plasma levels were present, with reappearance of an aldosterone postural response. Plasma renin activity and aldosterone plasma levels normalized 1 month later, with reappearance also of a plasma renin activity postural response and maintenance of normal potassium plasma levels even on a high sodium and normal potassium diet. The patient has remained hypertensive, although lower antihypertensive drug dosages have been employed. After 17 months, normal biochemical, hormonal and morphological findings were still present. Thus, we suggest PEI-CT as a further alternative approach to surgery in the management of carefully selected patients with APA.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.